PinX1 suppresses bladder urothelial carcinoma cell proliferation via the inhibition of telomerase activity and p16/cyclin D1 pathway

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Liu, Jian Ye ^a   Qian, Dong ^a,d   He, Li Ru ^a   Li, Yong Hong ^a   Liao, Yi Ji ^a   Mai, Shi Juan ^a   Tian, Xiao Peng ^a   Liu, Yan Hui ^b   Zhang, Jia Xing ^c   Kung, Hsiang Fu ^a   Zeng, Yi Xin ^a   Zhou, Fang Jian ^a   Xie, Dan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

p16 cyclin D1 pathway; PinX1; Prognosis; Telomerase activity; Urothelial carcinoma of bladder

Indexed keywords

CYCLIN D1; KI 67 ANTIGEN; MESSENGER RNA; PROTEIN P16; TELOMERASE; TELOMERIC REPEAT BINDING FACTOR 1; TELOMERIC REPEAT BINDING FACTOR 1 INTERACTING TELOMERASE INHIBITOR 1; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER CLASSIFICATION; CANCER INHIBITION; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIUM; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TELOMERE; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANIMALS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM TRANSPLANTATION; PROPORTIONAL HAZARDS MODELS; SIGNAL TRANSDUCTION; TELOMERASE; TELOMERE HOMEOSTASIS; TUMOR SUPPRESSOR PROTEINS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84887882278     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-148     Document Type: Article

References (35)

1. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006, 3:327-340. 10.1038/ncpuro0510, 16763645.
2. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol 2005, 15:10-18. 10.1016/j.semradonc.2004.07.009, 15662602.
3. Dimopoulos MA, Moulopoulos LA. Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder. J Clin Oncol 1998, 16:1601-1612.
4. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
5. Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, et al. Focus on bladder cancer. Cancer Cell 2004, 6:111-116. 10.1016/j.ccr.2004.08.002, 15324694.
6. Baffa R, Santoro R, Bullrich F, Mandes B, Ishii H, Croce CM. Definition and refinement of chromosome 8p regions of loss of heterozygosity in gastric cancer. Clin Cancer Res 2000, 6:1372-1377.
7. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993, 53:3869-3873.
8. Bova GS, MacGrogan D, Levy A, Pin SS, Bookstein R, Isaacs WB. Physical mapping of chromosome 8p22 markers and their homozygous deletion in a metastatic prostate cancer. Genomics 1996, 35:46-54. 10.1006/geno.1996.0321, 8661103.
9. Kishimoto Y, Shiota G, Wada K, Kitano M, Nakamoto K, Kamisaki Y, Suou T, Itoh T, Kawasaki H. Frequent loss in chromosome 8p loci in liver cirrhosis accompanying hepatocellular carcinoma. J Cancer Res Clin Oncol 1996, 122:585-589. 10.1007/BF01221189, 8879255.
10. MacGrogan D, Levy A, Bova GS, Isaacs WB, Bookstein R. Structure and methylation-associated silencing of a gene within a homozygously deleted region of human chromosome band 8p22. Genomics 1996, 35:55-65. 10.1006/geno.1996.0322, 8661104.
11. Zhang B, Bai YX, Ma HH, Feng F, Jin R, Wang ZL, Lin J, Sun SP, Yang P, Wang XX, et al. Silencing PinX1 compromises telomere length maintenance as well as tumorigenicity in telomerase-positive human cancer cells. Cancer Res 2009, 69:75-83.
12. Chang J, Dinney CP, Huang M, Wu X, Gu J. Genetic variants in telomere-maintenance genes and bladder cancer risk. PLoS One 2012, 7:e30665. 10.1371/journal.pone.0030665, 3281862, 22363464.
13. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, Wen JM, Fang Y, Hu L, Guan XY. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003, 107:896-902. 10.1002/ijc.11514, 14601048.
14. Tang DJ, Hu L, Xie D, Wu QL, Fang Y, Zeng Y, Sham JS, Guan XY. Oncogenic transformation by SEI-1 is associated with chromosomal instability. Cancer Res 2005, 65:6504-6508. 10.1158/0008-5472.CAN-05-0351, 16061626.
15. Ma Y, Wu L, Liu C, Xu L, Li D, Li JC. The correlation of genetic instability of PINX1 gene to clinico-pathological features of gastric cancer in the Chinese population. J Cancer Res Clin Oncol 2009, 135:431-437. 10.1007/s00432-008-0471-6, 18784941.
16. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010, 101:1543-1549. 10.1111/j.1349-7006.2010.01560.x, 20367640.
17. Qian D, Zhang B, He LR, Cai MY, Mai SJ, Liao YJ, Liu YH, Lin MC, Bian XW, Zeng YX, et al. The telomere/telomerase binding factor PinX1 is a new target to improve the radiotherapy effect of oesophageal squamous cell carcinomas. J Pathol 2013, 229:765-774. 10.1002/path.4163, 23341363.
18. Lin HS, Berry GJ, Sun Z, Fee WE. Cyclin D1 and p16 expression in recurrent nasopharyngeal carcinoma. World J Surg Oncol 2006, 4:62. 10.1186/1477-7819-4-62, 1569377, 16953893.
19. Fu ZJ, Ma ZY, Wang QR, Lei DP, Wang R, Liu CX, Pan XL. Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. Clin Exp Metastasis 2008, 25:887-892. 10.1007/s10585-008-9207-x, 18787961.
20. Zhou XZ, Lu KP. The Pin2/TRF1-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2001, 107:347-359. 10.1016/S0092-8674(01)00538-4, 11701125.
21. Zhou XZ, Huang P, Shi R, Lee TH, Lu G, Zhang Z, Bronson R, Lu KP. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest 2011, 121:1266-1282. 10.1172/JCI43452, 3069765, 21436583.
22. Chang Q, Pang JC, Li J, Hu L, Kong X, Ng HK. Molecular analysis of PinX1 in medulloblastomas. Int J Cancer 2004, 109:309-314. 10.1002/ijc.11689, 14750185.
23. Liao C, Zhao MJ, Zhao J, Song H, Pineau P, Marchio A, Dejean A, Tiollais P, Wang HY, Li TP. Mutation analysis of novel human liver-related putative tumor suppressor gene in hepatocellular carcinoma. World J Gastroenterol 2003, 9:89-93.
24. Park WS, Lee JH, Park JY, Jeong SW, Shin MS, Kim HS, Lee SK, Lee SN, Lee SH, Park CG, et al. Genetic analysis of the liver putative tumor suppressor (LPTS) gene in hepatocellular carcinomas. Cancer Lett 2002, 178:199-207. 10.1016/S0304-3835(01)00841-2, 11867205.
25. Hawkins GA, Chang BL, Zheng SL, Isaacs SD, Wiley KE, Bleecker ER, Walsh PC, Meyers DA, Xu J, Isaacs WB. Mutational analysis of PINX1 in hereditary prostate cancer. Prostate 2004, 60:298-302. 10.1002/pros.20075, 15264240.
26. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005, 365:687-701.
27. Morgan DO. Principles of CDK regulation. Nature 1995, 374:131-134. 10.1038/374131a0, 7877684.
28. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res 2011, 19:217-223. 10.3727/096504011X12970940207841, 21542457.
29. Haluska FG, Tsao H, Wu H, Haluska FS, Lazar A, Goel V. Genetic alterations in signaling pathways in melanoma. Clin Cancer Res 2006, 12:2301s-2307s. 10.1158/1078-0432.CCR-05-2518, 16609049.
30. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, Sini MC, Palla M, Mozzillo N, Ascierto PA. Main roads to melanoma. J Transl Med 2009, 7:86. 10.1186/1479-5876-7-86, 2770476, 19828018.
31. Wikman H, Kettunen E. Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer. Expert Rev Anticancer Ther 2006, 6:515-530. 10.1586/14737140.6.4.515, 16613540.
32. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Blood 1995, 86:841-854.
33. Zuo L, Weger J, Yang Q, Goldstein AM, Tucker MA, Walker GJ, Hayward N, Dracopoli NC. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12:97-99. 10.1038/ng0196-97, 8528263.
34. Paggi MG, Baldi A, Bonetto F, Giordano A. Retinoblastoma protein family in cell cycle and cancer: a review. J Cell Biochem 1996, 62:418-430. 10.1002/(SICI)1097-4644(199609)62:3<418::AID-JCB12>3.0.CO;2-E, 8872613.
35. Song X, Tao YG, Zeng L, Deng XY, Lee LM, Gong JP, Wu Q, Cao Y. Latent membrane protein 1 encoded by Epstein-Barr virus modulates directly and synchronously cyclin D1 and p16 by newly forming a c-Jun/Jun B heterodimer in nasopharyngeal carcinoma cell line. Virus Res 2005, 113:89-99. 10.1016/j.virusres.2005.04.019, 15936839.